*As of 11/13/2024
Remarks from Representative Deborah Ross | 3:00 PM - 3:45 PM
Defending Against Willful Infringement: The Impact of Patent Opinions in a Shifting Legal Landscape | 3:45 PM - 5:00 PM
Sponsored By:
This panel will explore the evolving importance of patent opinions in defending against willful infringement claims, especially in light of recent case law. We'll discuss how shifts from Underwater Devices to Seagate to Halo and SRI v. Cisco have redefined the standards for willfulness and enhanced damages, with recent cases underscoring the importance of an infringer's knowledge, pre-suit actions, and the quality of noninfringement defenses. Attendees will gain practical insights for demonstrating good faith via counsel opinions and strategic considerations for seeking to defeat assertions of willful infringement.
Moderator:
- Jonathan McMichael, Associate, Litigation– Fenwick
Speakers:
- Jessica Kaempf, Associate, Litigation– Fenwick
- Melissa Brand, Intellectual Property Counsel – Radius Health, Inc
- David Pauling, General Counsel, Sutro Biopharma
If I Were a Judge… : Case Law Updates | 9:00 AM - 10:15 AM
Sponsored By:
The panel will present and comment on a variety of patent litigation decisions with implications for BIO companies. The issues will include litigation strategy issues like expert selection and the odds of success on a preliminary injunction. We will also discuss the availability of patent royalties post-expiration and the evergreen questions of Section 101 patentable subject matter and Section 112 enablement. The audience will have a chance to weigh in on how they might shape patent jurisprudence should they be nominated to the federal bench!
Moderator:
- Eric Marandett, IP Litigation Group Co-Chair – Choate, Hall & Stewart LLP
Speakers:
- Anita Spieth, IP Litigation Group Co-Chair – Choate, Hall & Stewart LLP
- Christine Bellon, Chief Legal Officer – Beam Therapeutics
- Pamela Torpey, Principal, Patent Counsel - Sanofi
Biosimilars: Patents, Regulations, Litigation | 10:30 AM - 11:45 AM
Sponsored by:
We will cover strategies for biosimilars patent litigation, including preparing for potential litigation that may be years away and in multiple jurisdictions around the world. In addition, we will discuss legislative and policy matters, including the impact of the Inflation Reduction Act and the potential impacts of proposed legislation directed to access. And we will cover FDA matters, including interchangeability, labelling requirements and skinny labelling.
Moderator:
- Matthew Pearson, Partner - Akin
Speakers:
- Anna Abram, Senior Advisor, Public Law and Policy – Akin
- Paul Golian, Vice President & Assistant General Counsel, Intellectual Property - BMS
- Angie Verrecchio, Senior Counsel, Patent Litigation - Johnson & Johnson
Networking Lunch Buffet | 11:45 AM - 1:00 PM
* With remarks from featured guest the Hon. Pauline Newman, U.S. Circuit Judge
What Comes Next? American Competitiveness in the Next Administration | 1:00 PM - 2:15 PM
Sponsored by:
Among the many changes anticipated in the next administration, perhaps the most important will be the very different approaches the two candidates have advocated regarding America’s place in a competitive global economy now that we know who will be President. Panelists will discuss various aspects of this question – including technology areas, approaches for fostering competitiveness and whether cooperation or confrontation will be used to protect American interests at home and abroad. The interaction of the Congress, the Administration, and the Judiciary (especially the Supreme Court and Federal Circuit) will be evaluated.
Moderator:
- Kevin Noonan, Biotech and Pharma Practice Group Co-Chair - McDonnel Boehnen Hulbert & Berghoff LLP
Speakers:
- Stephen Ezell, Vice President, Global Innovation Policy, and Director, Center for Life Sciences Innovation - Information Technology and Innovation Foundation (ITIF)
- Jeffrey E. Depp, JD, MSIA, PhD Candidate, Public & International Affairs - AUTM Public Policy Legal Task Force, Edison Fellow - Center for Intellectual Property x Innovation Policy (C-IP2), and Consultant - Center for Strategic and International Studies (CSIS)
- Corey Salsberg, Vice President, Global Head IP Affairs - Novartis
Empowering Patients and Driving Pharmaceutical Progress: A Multi-Stakeholder Dialogue | 2:30 PM - 3:45 PM
Sponsored by:
This moderated discussion will address the evolving role of patient advocacy groups and foundations during research and drug development including grants, donations, and other research funding; equity positions in companies; working with patient communities on clinical trial design and recruitment; and patient representation on company advisory boards.
Moderator:
- Barbara Fiacco, Partner, Co-Chair of Intellectual Property Department, and Co-Chair of Patent, Trade Secrets, and Related Rights Litigation Practice - Foley Hoag LLP
Speakers:
- Javeed Froozan, VP, Business Development and Strategic Alliances - The Leukemia and Lymphoma Society, Inc. & LLS TAP, LLC
- Scott Carmer, CEO – T1D NewCo
- Karin Hoelzer, Senior Director, Patient Advocacy – Biotechnology Innovation Organization (BIO)
The UPC as a New EU Patent Litigation Forum: What we can Learn from the First Decisions and Life Science Cases After the First Year of the UPC | 8:30 AM - 9:45 AM
Sponsored by:
The panel explores the impact of the Unified Patent Court (UPC) on patent litigation in Europe in its first 1 ½ years by highlighting the most important trends and decisions and providing practical insights from df-mp partners involved in UPC cases. Biogen’s Chief IP Counsel Jennifer Grant Moitoso adds her in-house perspective on the UPC.
Moderator:
- Sandra Pohlman, Partner – df-mp
Speakers:
- Elisabeth Greiner, partner – df-mp
- H. Ulrich Dörries, Partner – df-mp
- Jennifer Grant Moitoso, SVP, Chief Intellectual Property Counsel – Biogen
The IP Agenda for the 119th Congress | 10:00 AM - 11:15 AM
The panel will explore the legislative landscape and prospects for action in the new Congress.
Moderator:
- David Lachmann,Senior Director, Federal Government Relations – Biotechnology Innovation Organization (BIO)
Speakers:
- Jacqui Kappler, Democratic Counsel for the IP Subcommittee
- John Lee, Majority Counsel, Subcommittee on Courts, Intellectual Property, and the Internet
- Tom Stoll, Director, Federal Government Affairs – Genentech, A Member of the Roche Group